Date: 2017-01-20
Type of information: Private placement
Company: Affimed (Germany)
Investors:
Amount:
Funding type: private placement
Planned used:
Others: * On January 20, 2017, Affimed announced the pricing of its previously announced public offering of 10,000,000 of its common shares at a public offering price of $1.80 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be approximately $16.9 million. The offering is expected to close on or about January 25, 2017, subject to customary closing conditions. BMO Capital Markets Corp. and Wells Fargo Securities, LLC are acting as joint book-running managers, and Trout Capital LLC is acting as co-manager. A shelf registration statement relating to these securities filed with the Securities and Exchange Commission (SEC) was declared effective by the SEC on October 23, 2015. The offering will be made only by means of a prospectus and prospectus supplement.
Therapeutic area: Cancer - Oncology
